- Home
- UNM vs EXEL Comparison
UNM vs EXEL Comparison
Compare UNM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNM | EXEL |
|---|---|---|
| Founded | 1848 | 1994 |
| Country | United States | United States |
| Employees | 10910 | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | UNM | EXEL |
|---|---|---|
| Price | $75.29 | $41.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $94.27 | $46.45 |
| AVG Volume (30 Days) | 1.4M | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $13.66 |
| Revenue Next Year | $4.84 | $13.73 |
| P/E Ratio | $17.16 | ★ $15.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.81 | $32.38 |
| 52 Week High | $84.48 | $48.74 |
Technical Indicators
Market Signals| Indicator | UNM | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 46.42 |
| Support Level | $72.54 | $40.01 |
| Resistance Level | $79.92 | $44.15 |
| Average True Range (ATR) | 2.17 | 1.23 |
| MACD | 0.31 | -0.08 |
| Stochastic Oscillator | 97.74 | 40.19 |
Price Performance
Historical ComparisonAbout UNM Unum Group
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The Unum USA segment generates the majority of revenue. The firm markets its products through brokers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.